{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:58:31Z","timestamp":1744520311148,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00105-021-04863-9","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T07:02:51Z","timestamp":1627542171000},"page":"647-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hidradenitis suppurativa\/Acne inversa: Von \u201eorphan disease\u201c zu heilbarer entz\u00fcndlicher Hauterkrankung","Hidradenitis suppurativa\/acne inversa: From \u201corphan disease\u201d to a\u00a0curable inflammatory skin disorder"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"Christos C.","family":"Zouboulis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"von Stebut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"issue":"suppl 1","key":"4863_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/exd.14340","volume":"30","author":"NS Chandran","year":"2021","unstructured":"Chandran\u00a0NS, Lee\u00a0JH, Kurokawa\u00a0I (2021) Hidradenitis suppurativa in south-east asia and east asia. Exp Dermatol 30(suppl 1):23\u201326","journal-title":"Exp Dermatol"},{"key":"4863_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-021-04864-8","author":"P Cramer","year":"2021","unstructured":"Cramer P, Schneider-Burrus S, Kov\u00e1cs M, Scholl L, Podda M, Bechara FG (2021) Hidradenitis suppurativa\/ Acne inversa \u2013 operative Optionen, Rekonstruktionen und die Kombination mit medikament\u00f6sen Therapien \u2013 Ein Update. Hautarzt. https:\/\/doi.org\/10.1007\/s00105-021-04864-8","journal-title":"Hautarzt"},{"key":"4863_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/derm.2.1.12490","volume":"2","author":"S Fimmel","year":"2010","unstructured":"Fimmel\u00a0S, Zouboulis\u00a0CC (2010) Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2:9\u201316","journal-title":"Dermatoendocrinol"},{"key":"4863_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677","author":"A Jfri","year":"2021","unstructured":"Jfri\u00a0A, Nassim\u00a0D, O\u2019Brien\u00a0E, Gulliver\u00a0W, Nikolakis\u00a0G, Zouboulis\u00a0CC (2021) Prevalence of hidradenitis suppurativa: a systematic review and meta-regression study. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1677","journal-title":"JAMA Dermatol"},{"key":"4863_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-021-04861-x","author":"E Just","year":"2021","unstructured":"Just E, Winkler T (2021) Acne inversa: eine seltene Erkrankung mit weitreichenden Auswirkungen f\u00fcr die Betroffenen \u2013 Erkenntnisse und W\u00fcnsche von Patienten. Hautarzt. https:\/\/doi.org\/10.1007\/s00105-021-04861-x","journal-title":"Hautarzt"},{"key":"4863_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-021-04851-z","author":"N Kirsten","year":"2021","unstructured":"Kirsten N, Frings V, Nikolakis G et\u00a0al (2021) Epidemiologie, Patientenlebensqualit\u00e4t und Behandlungskosten der Hidradenitis suppurativa\/Acne inversa. Hautarzt. https:\/\/doi.org\/10.1007\/s00105-021-04851-z","journal-title":"Hautarzt"},{"key":"4863_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2340\/00015555-1800","volume":"94","author":"CB Kromann","year":"2014","unstructured":"Kromann\u00a0CB, Ibler\u00a0KS, Kristiansen\u00a0VB, Jemec\u00a0GBE (2014) The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 94:553\u2013557","journal-title":"Acta Derm Venereol"},{"key":"4863_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-021-04850-0","author":"H Kurzen","year":"2021","unstructured":"Kurzen H, Fritz K, Altenburg A (2021) Hidradenitis suppurativa\/Acne inversa in der Praxis. Hautarzt. https:\/\/doi.org\/10.1007\/s00105-021-04850-0","journal-title":"Hautarzt"},{"key":"4863_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0625.2008.00712_1.x","volume":"17","author":"H Kurzen","year":"2008","unstructured":"Kurzen\u00a0H, Kurokawa\u00a0I, Jemec\u00a0GBE et\u00a0al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455\u2013472","journal-title":"Exp Dermatol"},{"key":"4863_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","volume":"62","author":"\u0141 Matusiak","year":"2010","unstructured":"Matusiak \u0141, Bieniek\u00a0A, Szepietowski\u00a0JC (2010) Hidradenitis suppurativa markedly decreases quality of life and professional activity. J\u00a0Am Acad Dermatol 62:706\u2013708","journal-title":"J Am Acad Dermatol"},{"key":"4863_CR11","doi-asserted-by":"publisher","DOI":"10.1159\/000509873","author":"G Nikolakis","year":"2020","unstructured":"Nikolakis\u00a0G, Kaleta\u00a0KP, Vaiopoulos\u00a0A et\u00a0al (2020) Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: different faces of the same disease? A systematic review. Dermatology. https:\/\/doi.org\/10.1159\/000509873","journal-title":"Dermatology"},{"key":"4863_CR12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s00105-020-04679-z","volume":"71","author":"G Nikolakis","year":"2020","unstructured":"Nikolakis\u00a0G, Karagiannidis\u00a0I, Vaiopoulos\u00a0AG, Becker\u00a0M, Zouboulis\u00a0CC (2020) Endokrine Mechanismen bei der Pathophysiologie der Hidradenitis suppurativa. Hautarzt 71:762\u2013771","journal-title":"Hautarzt"},{"key":"4863_CR13","doi-asserted-by":"publisher","unstructured":"Nikolakis G, Kokolakis G, Kaleta K et\u00a0al (2021) Pathogenese der Hidradenitis suppurativa\/Acne inversa. Hautarzt 72. https:\/\/doi.org\/10.1007\/s00105-021-04853-x","DOI":"10.1007\/s00105-021-04853-x"},{"key":"4863_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2340\/00015555-2591","volume":"97","author":"G Nikolakis","year":"2017","unstructured":"Nikolakis\u00a0G, Liakou\u00a0AI, Bonovas\u00a0S et al (2017) Bacterial colonization in hidradenitis suppurativa\/acne inversa: a cross-sectional study of 50\u00a0patients and review of the literature. Acta Derm Venereol 97:493\u2013498","journal-title":"Acta Derm Venereol"},{"key":"4863_CR15","doi-asserted-by":"publisher","unstructured":"Nikolakis G, von Stebut E (2021) Lokale und neue apparative Therapien der milden Hidradenitis suppurativa. Hautarzt 72. https:\/\/doi.org\/10.1007\/s00105-021-04849-7","DOI":"10.1007\/s00105-021-04849-7"},{"key":"4863_CR16","doi-asserted-by":"publisher","unstructured":"Pinter A, Mrowietz U, Volz T (2021) Systemische Therapie der mittelschweren\/schweren Hidradenitis suppurativa. Hautarzt 72. https:\/\/doi.org\/10.1007\/s00105-021-04844-y","DOI":"10.1007\/s00105-021-04844-y"},{"key":"4863_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","volume":"59","author":"JE Revuz","year":"2008","unstructured":"Revuz\u00a0JE, Canoui-Poitrine\u00a0F, Wolkenstein\u00a0P et al (2008) Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J\u00a0Am Acad Dermatol 59:596\u2013601","journal-title":"J Am Acad Dermatol"},{"key":"4863_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjd.17101","volume":"181","author":"T Tzellos","year":"2019","unstructured":"Tzellos\u00a0T, Yang\u00a0H, Mu\u00a0F, Calimlim\u00a0B, Signorovitch\u00a0J (2019) Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol 181:147\u2013514","journal-title":"Br J Dermatol"},{"key":"4863_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13555-020-00354-2","volume":"10","author":"T Tzellos","year":"2020","unstructured":"Tzellos\u00a0T, Zouboulis\u00a0CC (2020) Review of comorbidities of hidradenitis suppurativa: Implications for daily clinical practice. Dermatol Ther (Heidelb) 10:63\u201371 (Erratum: 2020;10:523)","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4863_CR20","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1111\/jdv.16520","volume":"34","author":"AG Vaiopoulos","year":"2020","unstructured":"Vaiopoulos\u00a0AG, Nikolakis\u00a0G, Zouboulis\u00a0CC (2020) Hidradenitis suppurativa in pediatric patients: a\u00a0retrospective monocentric study in Germany and review of the literature. J\u00a0Eur Acad Dermatol Venereol 34:2140\u20132146","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4863_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/jid.2012.255","volume":"133","author":"BG Vazquez","year":"2013","unstructured":"Vazquez\u00a0BG, Alikhan\u00a0A, Weaver\u00a0AL et al (2013) Incidence of hidradenitis suppurativa and associated factors: a\u00a0population-based study of Olmsted County, Minnesota. J\u00a0Invest Dermatol 133:97\u2013103","journal-title":"J Invest Dermatol"},{"key":"4863_CR22","doi-asserted-by":"publisher","unstructured":"von Laffert M, Hunger RE, Navarini AA, Zouboulis CC (2021) Klinische, pathologische und molekulare Biomarker der Hidradenitis suppurativa\/Acne inversa. Hautarzt 72. https:\/\/doi.org\/10.1007\/s00105-021-04848-8","DOI":"10.1007\/s00105-021-04848-8"},{"issue":"suppl 1","key":"4863_CR23","first-page":"5","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis\u00a0CC (2021) 10th European Hidradenitis Suppurativa (EHSF) e.\u202fV. Conference: a jubilee scientific event. Exp Dermatol 30(suppl 1):5\u20137","journal-title":"Exp Dermatol"},{"issue":"Suppl 5","key":"4863_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1610-0387.2012.08006.x","volume":"10","author":"CC Zouboulis","year":"2012","unstructured":"Zouboulis\u00a0CC, Bechara\u00a0FG, Fritz\u00a0K et al (2012) S1 \u2013 Leitlinie zur Therapie der Hidradenitis suppurativa\/Acne inversa (ICD-10 Ziffer: L73.2). J\u00a0Dtsch Dermatol Ges 10(Suppl 5):S1\u2013S31","journal-title":"J Dtsch Dermatol Ges"},{"key":"4863_CR25","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis\u00a0CC, Benhadou\u00a0F, Byrd\u00a0A et\u00a0al (2020) What causes hidradenitis suppurativa? 15\u00a0years after. Exp Dermatol 29:1154\u20131170","journal-title":"Exp Dermatol"},{"key":"4863_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis\u00a0CC, del Marmol\u00a0V, Mrowietz\u00a0U, Prens\u00a0E, Tzellos\u00a0T, Jemec\u00a0GBE (2015) Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184\u2013190","journal-title":"Dermatology"},{"issue":"suppl 1","key":"4863_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/exd.14338","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis\u00a0CC, Frew\u00a0JW, Giamarellos-Bourboulis\u00a0EJ et al (2021) Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 30(suppl 1):8\u201317","journal-title":"Exp Dermatol"},{"issue":"suppl 1","key":"4863_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/exd.14341","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis\u00a0CC, Goyal\u00a0M, Byrd\u00a0AS (2021) Hidradenitis suppurativa in skin of color. Exp Dermatol 30(suppl 1):27\u201330","journal-title":"Exp Dermatol"},{"key":"4863_CR29","first-page":"e251","volume":"35","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis\u00a0CC, Nogueira da Costa\u00a0A (2021) Drug repurposing through drug-gene interaction profiles for hidradenitis suppurativa\/acne inversa treatment. J\u00a0Eur Acad Dermatol Venereol 35:e251\u2013e254","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4863_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bjd.19627","volume":"184","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis\u00a0CC, Readhead\u00a0B, Dudley\u00a0JT (2021) An additional drug repurposing study for hidradenitis suppurativa\/acne inversa. Br J Dermatol 184:748\u2013750","journal-title":"Br J Dermatol"},{"key":"4863_CR31","doi-asserted-by":"publisher","unstructured":"Zouboulis CC, von Stebut E (2021) Bedarf von Real-World-klinischen Studien f\u00fcr die Hidradenitis suppurativa\/Acne inversa. Hautarzt 72. https:\/\/doi.org\/10.1007\/s00105-021-04847-9","DOI":"10.1007\/s00105-021-04847-9"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04863-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04863-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04863-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T07:06:00Z","timestamp":1627542360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04863-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4863"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04863-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"type":"print","value":"0017-8470"},{"type":"electronic","value":"1432-1173"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"assertion":[{"value":"17 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C.\u00a0Zouboulis hat Berater- und Vortragshonorare von Idorsia, Incyte, Inflarx, Janssen, Novartis, Regeneron und UCB erhalten, die nicht mit diesem Manuskript in Verbindung stehen. Seine Abteilung erhielt Honorare von AbbVie, Inflarx, Novartis and UCB f\u00fcr seine Teilnahme an klinischen Studien. E.\u00a0von Stebut hat Berater- und Vortragshonorare von Almirall, Infectopharm, Janssen, Leo Pharma und Novartis erhalten, die nicht mit diesem Manuskript in Verbindung stehen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}